Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial and Pipeline Insight - ADHD - Immature adult market continues to offer greatest commercial potential (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 10/04/2008
- Report Title: Commercial and Pipeline Insight - ADHD - Immature adult market continues to offer greatest commercial potential
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 211
Introduction
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving patients and physicians a greater choice of treatment options.
Scope
Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs. Analysis of patient potential, unmet needs and clinical trial design in the ADHD market. Overview of key marketed brands and late stage pipeline drugs. Identification of future market events that are expected to affect ADHD revenues.
Highlights
Estimated to be twice the size of the pediatric ADHD population, the highly prevalent, yet largely untapped, adult ADHD population continues to represent an attractive niche to target. The rising awareness of ADHD brought about by marketing campaigns for Adderall XR and Strattera has paved the way for the entry of additional adult ADHD drugs.
Due to a lack of innovation, none of the forecast drugs have the potential to match the commercial success experienced by currently marketed brands. Shire's Intuniv (guanfacine) is expected to be positioned as a second-line treatment and will benefit from the company's established reputation in the market.
J&J's Concerta's strong uptake is due to its first-to-market status as a once-daily ADHD treatment. Anticipated approval for use in adult patients, combined with Adderall XR's patent expiry will see Concerta becoming the market leader by 2017. However, owing to patent litigations, the timing of Concerta's genericization remains uncertain.
Reasons to Purchase
Benchmark key late-stage pipeline ADHD drugs against current market leading brands. Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the ADHD market based on key opinion leader comments.
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
